Abstract
Background To estimate the seroprevalence of SARS-CoV-2 infection in May-June 2020 after the lockdown in adults living in three regions in France and to identify the associated risk factors.
Methods Participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) - two regions with high rate of COVID-19, or in the Nouvelle-Aquitaine (NA) – with a low rate, were asked to take a dried-blood spot (DBS) for anti-SARS-CoV-2 antibodies assessment.
The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). The secondary outcomes were a positive ELISA IgG against the nucleocapsid protein (ELISA-NP), anti-SARS-CoV-2 neutralizing antibodies titers ≥40 (SN), and predicted positivity obtained from a multiple imputation model (MI). Prevalence estimates were adjusted using sampling weights and post-stratification methods.
Findings Between May 4, 2020 and June 23, 2020, 16,000 participants were asked to provide DBS, and 14,628 were included in the analysis, 983 with a positive ELISA-S, 511 with a positive ELISA-NP, 424 with SN≥40 and 941±31 with a positive MI. Adjusted estimates of seroprevalence (positive ELISA-S) were 10.0% (95%CI 9.1%;10.9%) in IDF, 9.0% (95%CI 7.7%; 10.2%) in GE and 3.1% (95%CI 2.4%; 3.7%), in NA. The adjusted prevalence of positive ELISA-NP, SN and MI were 5.7%, 5.0% and 10.0% in IDF, 6.0%, 4.3% and 8.6% in GE, and 0.6%, 1.3% and 2.5% in NA, respectively. A higher seroprevalence was observed in younger participants and when at least one child or adolescent lived in the same household. A lower seroprevalence was observed in smokers compared to non-smokers.
Interpretation At the end of the lockdown the prevalence of anti-SARS-CoV-2 IgG or neutralizing antibodies remained low in the French adult population, even in regions with high reported rates of COVID-19.
Competing Interest Statement
Prof Fabrice Carrat reports personal fees from Imaxio and Sanofi, outside the submitted work. All other authors declare no competing interest
Clinical Trial
Funding Statement
This study was funded by ANR (Agence Nationale de la Recherche, #ANR-20-COVI-000, #ANR-10-COHO-06), Fondation pour la Recherche Medicale (#20RR052-00), Inserm (Institut National de la Sante et de la Recherche Medicale, #C20-26).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The SAPRIS survey was approved by the Inserm ethics committee (approval #20-672 dated March 30, 2020). The SAPRIS-SERO study was approved by the Sud-Mediterranee III ethics committee (approval #20.04.22.74247) and electronic informed consent was obtained from all participants for DBS testing.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* co-last authors
Email addresses fabrice.carrat{at}iplesp.upmc.fr
xavier.de-lamballerie{at}univ-amu.fr
Delphine.RAHIB{at}santepubliquefrance.fr
helene.blanche{at}fjd-ceph.org
nathanael.lapidus{at}iplesp.upmc.fr
fanny.artaud{at}inserm.fr
sofiane.kab{at}inserm.fr
adeline.renuy{at}inserm.fr
f.szabo{at}uren.smbh.univ-paris13.fr
laurence.meyer{at}inserm.fr
Nathalie.LYDIE{at}santepubliquefrance.fr
marie-aline.charles{at}inserm.fr
pierre-yves.ancel{at}inserm.fr
florence.jusot{at}dauphine.psl.eu
alex.rouquette{at}gmail.com
stephane.priet{at}univ-amu.fr
marielasaba{at}gmail.com
toscane.fourie{at}gmail.com
clovis.lusivika{at}iplesp.upmc.fr
jerome.nicol{at}iplesp.upmc.fr
stephane.le-got{at}inserm.fr
n.pecollo{at}eren.smbh.univ-paris13.fr
y.esseddik{at}eren.smbh.univ-paris13.fr
cindy.lai{at}inserm.fr
jean-marie.gagliolo{at}inserm.fr
Deleuze{at}cng.fr
nathalie.bajos{at}inserm.fr
gianluca.severi{at}inserm.fr
m.touvier{at}eren.smbh.univ-paris13.fr
marie.zins{at}inserm.fr
Data Availability
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request
